$90M series B sets Vigil up to advance TREM2 mAb, pursue IPO

With $90 million from a series B round led by Vida Ventures, Vigil plans to bring its TREM2 mAb to the clinic for the rare microgliopathy ALSP, advance its small molecule against the same target through IND, and expand its pipeline to additional targets and indications.

Vigil Neuroscience Inc. in-licensed two TREM2 agonists from Amgen Inc. (NASDAQ:AMGN) in July 2020. TREM2 acts as a damage sensor on microglia and mutations in the target are one of the biggest risk factors for late-onset Alzheimer’s disease, after APOE4...